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COMPARATIVE PROGNOSTIC SIGNIFICANCE OF SENTINEL LYMPH NODE BIOPSY AND AXILLARY 
LYMPHADENECTOMY IN CARCINOMA OF THE BREAST
Aaron D. Bleznak, MD, FACS1, Jennifer Bleznak2, Barbara Gutch, RN3, Aileen Galley, MSW3
1Section of Surgical Oncology, Lehigh Valley Hospital, Allentown, PA; 2Muhlenberg College, Allentown, PA; 3Mt. Nittany Medical Center
Purpose:
It has been hypothesized that the enhanced pathologic assessment 
and immunohistochemical staging performed for nodes identified by 
lymphatic mapping/sentinel lymph node biopsy will identify patients 
with small metastases, resulting in stage migration and improved 
outcomes for pN0(i-) patients as compared to those who are pN0 
by axillary lymphadenectomy.  This study compares the prognostic 
accuracies of axillary lymphadenectomy (ALND) and SLNB in patients 
with carcinoma of the breast, operated on by a single breast surgeon 
during the period 1991-2004.
Conclusions:
This data set demonstrates equivalent prognostic ability for sentinel 
node biopsy and axillary lymphadenectomy as assessed by disease-
free survival at a median follow-up of almost six years.  These two 
cohorts were statistically similar in age, stage of disease, grade 
of disease, and use of adjuvant systemic therapy.  Significant 
differences exist in the frequency of breast conserving surgery and 
radiation therapy, perhaps reflecting more frequent and sensitive 
screening mammography in the cohort operating upon from 1997-
2004.    
Methods:
An Institutional Review Board-approved retrospective analysis of 
a prospectively maintained database of breast cancer patients 
identified all node negative women operated upon from 1991-2004.  
This population included 135 women who underwent ALND from 
1991-1996 and 238 patients assessed by SLNB from 1997-2004.  The 
demographics of these cohorts were compared using Chi-Square 
analyses (MS Excel). Disease free status was calculated for both 
groups and compared.
Results:
The ALND and SLNB cohorts were statistically similar (Table 
1). Although there were no statistically significant differences in 
the demographics, women from the ALND cohort had a slight 
preponderance of T2 cancers.  The SLNB patients were more 
likely to have breast preservation (87% versus 64%, p < 0.01) and 
consequently were also more often treated with adjuvant radiation 
therapy (85% versus 61%, p = 0.03). Adjuvant chemotherapy (21% 
v. 16%) and endocrine therapy (49% v. 48%) were employed equally 
in these two cohorts.  In our study, 89.6% of the ALND cohort was 
disease free at a median follow-up of 130 months while 95.8% of the 
SLNB cohort was disease free at a median follow-up of 71 month.  
At a comparable median follow-up of 71 months, 92.2% of the 
ALND cohort was free of disease (p=0.73).
Table 1. Patient Demographics
 Axillary Lymph NodeDissection
Sentinel Lymph Node
Biopsy p value
N 135 239  
Age 61.3 60.5 NS
% ER Positive 108/130 (83%) 187/225 (83%) 0.16
Stage
     0 2 (1%) 13 (5%) 0.07
     1 108 (80%) 204 (85%) 0.57
     2 25 (19%) 22 (9%) 0.03
Grade 
     Well 37 (27%) 102 (43%) 0.05
     Moderate 53 (39%) 71 (30%) 0.02
     Poor 31 (23%) 54 (23%) 0.41
     N/D 14 (10%) 12 (5%)
Tx
     BCS 86 (64%) 208 (87%) <0.01
     MAST 49 (36%) 31 (13%) <0.01
     CT 28/135 (21%) 39/239 (16%) 0.33
     HT 66/134 (49%) 114/239 (48%) 0.64
     RT 82/135 (61%) 202/239 (85%) 0.03
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